10-Q quarterly report · filed Oct 28, 2026

Axogen, Inc. (AXGN) Q3 2026 10-Q Quarterly Report

Short answer

Axogen, Inc. (AXGN) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $76M (up 26.2% year over year) with net income of $2M.

Q3 2026 key financials · XBRL

Revenue
$76M
+26.2% YoY · +8.8% QoQ
Net income
$2M
+229.7% YoY · +254.0% QoQ
Operating margin
1.3%
Gross margin
74.8%
EPS (diluted)
$0.05
+400.0% YoY · +350.0% QoQ

Source: XBRL data from the Axogen, Inc. (AXGN) Q3 2026 10-Q on SEC EDGAR. USD.

Axogen, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $75,834, up $15,752 or 26.2% YoY, driven by higher unit volume and pricing
  • Gross margin 74.8% vs 76.6% YoY, pressured by higher product costs
  • Q3 net income $2,334, or 3.1% margin, vs $720, or 1.2% YoY
  • Cash, equivalents and investments $348,068, up from $41,528; nine-month operating cash flow $25,322 vs $(2,226)
  • $225,029 offering proceeds, $200,000 allocated to BioCircuit acquisition; trade disputes and macroeconomic instability potential headwinds

Risk Factors

  • Newly added merger-integration risk: BioCircuit acquisition may create costly, time-consuming integration challenges
  • Operational risk: Management distraction and integration disruptions could impair existing operations
  • Financial risk: Failure to realize anticipated Merger benefits could adversely affect financial condition and results of operations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Axogen, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.